regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and Novo Semaglutide in Winter Garden |
Description
MTHFR gene mutation is a common genetic variation that can impact folate metabolism and increase the risk of certain health conditions.
The supplier who manufactures your drug
The survival benefit was more pronounced in younger people and those with cardiometabolic comorbidities, highlighting the need for a careful riskbenefit evaluation when prescribing GLP-1 RAs in high-risk individuals.
See where to go and safety tips.
If youre taking Ozempic as part of a weight loss journey or blood sugar control, youve probably noticed one big changeyour appetite isnt
Our guide compares top telehealth options for weight management, GLP-1s, and more.
